Research to fight tuberculosis

LSHTM researchers have been awarded separately funded projects within TBVAC2020 to help support the discovery and development of novel TB vaccines: Greg Bancroft, Helen Fletcher/Andrea Zelmer, and Hazel Dockrell /Steven Smith.

TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. Read about the work here.

The European Commission has also produced a fact sheet on the fight against TB.

Fact sheet | The challenge

Tuberculosis (TB) is the leading infectious disease killer, taking the lives of 1.5 million people each year. 4000 people die of TB every day and up to 2 billion are infected with the causative agent, Mycobacterium tuberculosis. Of the 700 000 antimicrobial-resistance related deaths each year, almost one-third are due to multi-drug resistant TB (MDR-TB).

In 1993 the World Health Organization (WHO) designated TB a global public health emergency. The WHO END TB Strategy calls for a 90% reduction in TB deaths and an 80% reduction in TB incidence rate by 2030, compared with 2015. These goals can hardly be met, but the EU Framework Programmes for Research and Development can make a difference in accelerating development of new tools, vaccines, diagnostics and drugs, and to fight the successful pathogen M.tuberculosis and the disease it is causing.

Find out more information here.